Clinical Trial Update: An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia [Phase 2]

View source ↗

Summary

Phase 2 trial of BXCL501 for agitation associated with dementia was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation
• Dementia

Drugs mentioned

• BXCL501 (dexmedetomidine)

Snippet

Sponsor: BioXcel Therapeutics Inc | Conditions: Agitation, Dementia | Phase 2 | Status: TERMINATED | Results posted: 2023-08-25